International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoid malignancy.
• International collaboration is crucial for understanding risk factors in NLPHL across all age groups.

Purpose of the Study:

• To evaluate clinical risk factors and immunoarchitectural patterns (IAPs) in pediatric and adult NLPHL patients.
• To develop a prognostic score for NLPHL to guide treatment decisions.

Main Methods:

• Retrospective analysis of 2,243 NLPHL cases from 38 institutions (1992-2021).
• Assessment of progression-free survival (PFS), overall survival (OS), transformation rate, and lymphoma-specific death.
• Development and validation of the Lymphocyte-Predominant International Prognostic Score (LP-IPS) using Cox regression.

Main Results:

• Immunoarchitectural patterns (IAPs) were not significantly associated with PFS or OS, but IAP E increased transformation risk.
• The developed LP-IPS incorporates age, stage, hemoglobin, and splenic involvement.
• Higher LP-IPS scores were significantly associated with worse PFS, OS, and increased risk of transformation and lymphoma-specific death.

Conclusions:

• The LP-IPS is a validated tool for identifying high-risk NLPHL patients.
• The LP-IPS can inform prospective clinical trials for therapy de-escalation in low-risk NLPHL patients.